Results 151 to 160 of about 4,340 (195)

The Impact of <i>UGT1A1</i> Genetic Variability on Enzyme Expression in Liver Pathology. [PDF]

Genes (Basel)
Szeląg-Pieniek S, Kucak J, Malinowski D, Oswald S, Droździk M, Kurzawski M.   +5 more
europepmc   +1 more source

Commentary: Disulfidptosis-related gene signatures as prognostic biomarkers and predictors of immunotherapy response in HNSCC. [PDF]

Front Immunol
Xue J, Xue C, Yin Q, Chen L, Wang M.
europepmc   +1 more source

Epigenetic Regulation Through Histone Deacetylation: Implications and Therapeutic Potential in Hepatocellular Carcinoma. [PDF]

Cells
Sadia K, Castagna A, Udali S, Ambrosani F, Pattini P, Beri R, Argentino G, Masutti M, Moruzzi S, Friso S.   +9 more
europepmc   +1 more source

Design, synthesis, biological and in silico evaluation of 3‑carboxy‑coumarin sulfonamides as potential antiproliferative agents targeting HDAC6. [PDF]

Biomed Rep
Madrigal-Angulo JL, Hernández-Fuentes GA, Parra-Delgado H, Olvera-Valdéz M, Padilla-Martínez II, Cabrera-Licona A, Espinosa-Gil AS, Delgado-Enciso I, Martínez-Martínez FJ.   +8 more
europepmc   +1 more source

Histone and non-histone (de)acetylation impact on the blood-brain barrier. [PDF]

Fluids Barriers CNS
Melo M, Fortuna A, Laranjinha J, Bicker J.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Simple and Efficient Synthesis of Belinostat

Synthetic Communications, 2010
A novel synthesis of belinostat (1) starting from 3-nitrobenzaldehyde has been developed. The key step in this sequence involves the conversion of (2E)-3-(3-aminophenyl)acrylic acid methyl ester to (2E)-3-(3-chlorosulfonylphenyl)acrylic acid methyl ester via diazotization and sulfonylation.
Lei Yang, Xiaowen Xue, Yihua Zhang
exaly   +3 more sources

UGT genotyping in belinostat dosing [PDF]

Pharmacological Research, 2016
Certain genetic polymorphisms of UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) can reduce gene expression (*28, *60, *93) or activity (*6), thereby altering the pharmacokinetics, pharmacodynamics, and the risk of toxicities of UGT1A1 substrates, of which irinotecan is a widely-described example.
Andrew K L Goey
exaly   +3 more sources